Aernoud Fiolet

114 Chapter 4 40. Withdrawalof theMarketingAuthorisationApplicationforCanakinumabNovartis (Canakinumab). London; 2018. https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers- withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_en.pdf. Accessed March 30, 2019. 41. A. Janoudi, F.E. Shamoun, J.K. Kalavakunta, et al. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. Eur Heart J, 37 (25) (2016), pp. 1959-1967 42. S.M. Nidorf, P.L. Thompson. Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin Ther, 41 (1) (2019), pp. 41-48 43. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. In: Seminars in Arthritis and Rheumatism. Vol 43. Elsevier; 2013:387–391. 44. K.M. Jordan, J.S. Cameron, M. Snaith, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford), 46 (8) (2007), pp. 1372-1374 45. Demidowich AP, Levine JA, Onyekaba GI, et al. Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. Diabetes, Obes Metab. 2019;21(7):dom.13702. 46. M. Imazio, A. Brucato, P. Ferrazzi, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA, 312 (10) (2014), pp. 1016-1023 47. U.S. Food &Drug Administration. Postmarket Drug Safety Information for Patients and Providers - Colchicine (marketed as Colcrys) Information. June 30. 48. I.F.N. Hung,A.K.L.Wu,V.C.C. Cheng, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis, 41 (3) (2005), pp. 291- 300 49. Y. Solak, H. Atalay, Z. Biyik, et al. Colchicine toxicity in end-stage renal disease patients. AmJ Ther, 21 (6) (2014), pp. e189-e195 50. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446. 51. K.Wilbur,M.Makowsky. Colchicine myotoxicity: case reports and literature review. Pharmacother J Hum Pharmacol Drug Ther, 24 (12) (2004), pp. 1784-1792 52. A. Tufan, D.S. Dede, S. Cavus, et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother, 40 (7–8) (2006), pp. 1466-1469 53. S.K. Baker, S. Goodwin, M. Sur, et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle and Nerve, 30 (6) (2004), pp. 799-802 54. 54. A.T.L. Fiolet, S.M. Nidorf, A. Mosterd, et al. Colchicine in stable coronary artery disease. Clin Ther, 41 (1) (2019), pp. 30-40 55. ClinicalTrials.gov. Colchicine Cardiovascular Outcomes Trial (COLCOT). NCT02551094. https:// clinicaltrials.gov/ct2/show/NCT02551094. Published 2015. Accessed August 15, 2019. 56. ClinicalTrials.gov. Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry (CLEAR-SYNERGY). https://clinicaltrials.gov/ct2/show/NCT03048825. Published 2017. Accessed August 15, 2019. 57. ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). NCT02898610.